The Future Methods of Treating Hereditary Hair Loss

Posted by Admin

 

Men have been seeking an ultimate cure for hereditary hair loss for thousands of years but until very recently all available cures were either simple cosmetic cover-ups or unsophisticated supplement pills and herbal lotions, with many of them just being scams. It was only with the advent of finasteride and minoxidil and improvements made in hair transplantation in recent years that the new era began, enabling hair loss sufferers to halt the further progression of the balding process and replace the missing hair on top of their head using the hair left at the back of their scalp. However, to this day no ultimate cure for hereditary hair loss exists. There are presently several promising drugs and surgical techniques under development but none of these new therapies is expected to hit the market before 2011.

NEOSH101 is being developed by the US company Neosil and it is currently undergoing phase IIb clinical trials. NEOSH101 has been proven to be a more powerful and faster-acting, hair growth stimulant than minoxidil and it only needs applying once daily. Though significantly improving the current hair loss treatment options, NEOSH101 is not going to become an ultimate cure for hereditary hair loss. The clinical testing seems to be advancing slower than most hair loss sufferers would like and, hence, do not hold your breath for it hitting the market anytime soon. NEOSH101 is mainly expected to replace minoxidil and other currently available hair growth stimulants.

Another promising field of development is the telomerase research. Telomerase is an enzyme that is able to put natural caps on telomeres and thus protect them from shortening. Telomerase thereby helps maintain the genomic integrity. Shortened telomeres are associated with the premature aging processes. However, the uncontrolled activation of telomerase can cause cancer growth. Cancer research is the main focus of the telomerase study but scientists are also looking for other applications, such as anti-aging drugs and drugs against hereditary hair loss and gray hair. Although still under development, there are already some products commercially available that seek to emulate the mechanism of telomerase action but they have no scientific backing and should be avoided. Telomerase research could really change the world of medicine but its commercial application might be a good decade away.

Hair multiplication, often called hair cloning, is the next hopeful treatment approach being developed. This technique involves extracting the hair follicles from the back of the patient’s scalp, culturing and multiplying them and injecting the newly-grown, hair cells into the bald scalp. Among several teams of scientists on three continents researching hair multiplication, the UK healthcare company Intercytex appears to be the frontrunner. Intercytex reported results of the latest stage of the clinical phase II study of ICX-TRC (a suspension of a patient’s own dermal papilla cells) in March 2008 and they were quite positive. The next release is expected in Q4 2008. This therapy might hit the market in 2011 at the earliest. The main benefit of hair multiplication would be solving the shortage of donor hair that is the main limiting factor in hair transplantation.

Generating hair follicles in wounds of hair-free skin is a completely new approach to regrowing lost hair. It was discovered accidentally as wounded skin in mice started producing new hair. This technology is currently being developed by the US medical device company, Follica, which licensed this technology from the University of Pennsylvania. Though this approach may sound weird it only uses common instruments and drugs that have already been medically approved and thus it might not take too long for it to become available.

This is the list of only a few promising treatment options for hereditary hair loss that are being currently developed but many others are in the pipeline. It seems that becoming bald may soon be by choice rather than destiny.